Find participating medical centers and current study status in each of them

    Find participating medical centers

    A study to look at a new medicine called, “GDC-0134”, for treating patients with amyotrophic lateral sclerosis (ALS)

    A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

    • Neurodegenerative Disorder
    • Amyotrophic Lateral Sclerosis

    Basic Details

    Gender
    All
    Age
    ≥ 18 Years
    Healthy Volunteers
    No
    Sponsor Genentech, Inc.
    Phase Phase 1
    Study Identifier NCT02655614, GN29823, 2017-002931-41

    This clinical trial was done to study a new medicine called, “GDC-0134”, for the treatment of patients with amyotrophic lateral sclerosis (ALS). This study was done to find out how safe was it for patients with ALS to be treated with a new study medicine. Forty-nine patients took part in this study at 10 study centers in 3 countries.

    The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

    The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

    Results Disclaimer

    Find participating medical centers and current study status in each of them

      Find participating medical centers

      About Clinical Research

      In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.